Talking Tall Rounds®: Updates on Less Invasiv...

Luke Laffin, MD, speaks with Steven Nissen, MD, about findings from the ALPACA trial evaluating lepodisiran and its effects on oxidized phospholipids and lipoprotein(a). They discuss the potential mechanisms linking lipoprotein(a) to cardiovascular risk and how ongoing phase 3 re ...  Show more

Steven Nissen, MD, and Luke Laffin, MD, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol and triglycerides, and the potential role of one-time gene-ed ...  Show more

Obstructive hypertrophic cardiomyopathy therapy and septal reduction therapy via alcohol septal ablation and surgical myectomy is discussed by interventional cardiologist Dr. Amar Krishnaswamy and surgical perspective from cardiothoracic surgeon Dr. Per Wierup. Amit joins Dr. Lau ...  Show more

Congenital heart disease and pulmonic valve disease require a coordinated team approach that includes an initial evaluation, explanation of therapeutic options, innovative transcatheter and surgical therapies and consultative follow-up. Dr. Joanna Ghobrial discusses diagnosis and ...  Show more

KYW Newsradio’s Rasa Kaye discusses aortic valve disease with Deborah Heart and Lung Center's Interventional Cardiologist Dr. Richard Kovach. The conversation includes Deborah’s team approach to identifying, managing and treating the condition, and the latest advances in Trans ...

Drs Coats, Bozkurt, Metra, and Zieroth discuss important updates regarding the management of patients with heart failure.

Credit available for this activity expires: 11/22/2022
Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/vie ...